Bevacizumab Biosimilar Approved in Europe

January 19, 2018 – The European Commission has approved the bevacizumab biosimilar ABP 215 (bevacizumab-awwb; MVASI), for the treatment of patients across several tumor types. In November 2017, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of ABP-215, developed through a collaboration between Amgen and Allergan, for the treatment of patients the following tumor types … (leggi tutto)